Actuate Therapeutics, Inc. (ACTU) Price & Analysis

Compare

21 Followers

ACTU Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.47 - $11.99

Previous CloseN/A

Volume10.16K

Average Volume (3M)135.44K

Market Cap

$167.24M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.14

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.41

Shares Outstanding20,470,505

10 Day Avg. Volume80,579

30 Day Avg. Volume135,442

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$20.00

Price Target Upside147.83% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsEncouraging efficacy data in Ewing sarcoma with elraglusib achieving complete responses in a subset of patients.

Market PotentialActuate at the current valuation of $141M, with a revenue potential of nearly $600M by 2033, is undervalued and represents an attractive opportunity for a long-term investor.

Safety And EfficacyContinued favorable safety and tolerability profile could make elraglusib drug of choice.

Bears Say

Investment RisksRisks to the Buy rating include financial, clinical, manufacturing, legal and intellectual property, regulatory, competition, commercial, and pipeline challenges.

Regulatory ApprovalElraglusib could receive marketing approval for Ewing sarcoma if it successfully reiterates initial data in the Phase 2 study.

Actuate Therapeutics, Inc. News

Actuate, Incyte, University of Pittsburgh collaborate on elraglusib trial

Actuate Therapeutics (ACTU) announced the initiation of the Phase 1b trial of elraglusib in combination with Incyte’s (INCY)...

2d ago

ACTU

INCY

Actuate Therapeutics files to sell 1.33M shares of common stock for holders

16:02 EDT Actuate Therapeutics (ACTU) files to sell 1.33M shares of common stock for holders Published first on...

14d ago

ACTU

Actuate Therapeutics announces end of Phase 1 portion of elraglusib study

Actuate Therapeutics (ACTU) announced the end of the Phase 1 portion of its clinical study evaluating elraglusib monotherapy...

22d ago

ACTU

Promising Clinical Developments and Valuation Support Buy Rating for Actuate Therapeutics

H.C. Wainwright analyst Swayampakula Ramakanth has maintained their bullish stance on ACTU stock, giving a Buy rating on...

19d ago

ACTU

Actuate Therapeutics Secures $4.7M in Private Placement

Actuate Therapeutics, Inc. ( ($ACTU) ) has shared an update. On June 25, 2025, Actuate Therapeutics, Inc. entered...

1M ago

ACTU

Actuate highlights results from subgroup analysis of Phase 2 elraglusib trial

Actuate Therapeutics (ACTU) highlighted results from a pre-specified subgroup analysis of its Phase 2 trial of elraglusib in...

2M ago

ACTU

Actuate reports biomarker, machine learning data from Phase 2 elraglusib trial

Actuate Therapeutics (ACTU) announced biomarker data from a recent poster presentation at the American Society of Clinical Oncology...

2M ago

ACTU

Actuate Therapeutics announces inclusion in Russell 3000, 2000 indexes

Actuate Therapeutics (ACTU) announced that the Company will be added to the Russell 3000 Index, with automatic inclusion...

2M ago

ACTU

Actuate Therapeutics Hosts Key Opinion Leader Event

Actuate Therapeutics, Inc. ( ($ACTU) ) just unveiled an announcement. On May 31, 2025, Actuate Therapeutics hosted a...

2M ago

ACTU

Actuate Therapeutics shares highlights from KOL eventon elraglusib data

Actuate Therapeutics (ACTU) announced key takeaways from its Key Opinion Leader event held on May 31, 2025 discussing...

2M ago

ACTU

Actuate Therapeutics Reports Positive Phase 2 Trial Results

The latest announcement is out from Actuate Therapeutics, Inc. ( ($ACTU) ). On May 31, 2025, Actuate Therapeutics...

2M ago

ACTU

Promising Clinical Trial Results Justify Buy Rating for Actuate Therapeutics’ Elraglusib

Actuate Therapeutics, Inc. (ACTU – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst...

2M ago

ACTU

Actuate Therapeutics Elects Directors at Annual Meeting

Actuate Therapeutics, Inc. ( ($ACTU) ) just unveiled an update. On May 22, 2025, Actuate Therapeutics, Inc. held...

3M ago

ACTU

Actuate Therapeutics to host KOL event on Phase 2 elraglusib data

Actuate Therapeutics (ACTU) will host an in-person key opinion leader event, during the 2025 American Society of Clinical...

3M ago

ACTU

ACTU FAQ

What was Actuate Therapeutics, Inc.’s price range in the past 12 months?

Actuate Therapeutics, Inc. lowest stock price was $5.47 and its highest was $11.99 in the past 12 months.

What is Actuate Therapeutics, Inc.’s market cap?

Actuate Therapeutics, Inc.’s market cap is $167.24M.

When is Actuate Therapeutics, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Actuate Therapeutics, Inc.’s earnings last quarter?

Currently, no data Available

Is Actuate Therapeutics, Inc. overvalued?

According to Wall Street analysts Actuate Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Actuate Therapeutics, Inc. pay dividends?

Actuate Therapeutics, Inc. does not currently pay dividends.

What is Actuate Therapeutics, Inc.’s EPS estimate?

Actuate Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Actuate Therapeutics, Inc. have?

Actuate Therapeutics, Inc. has 20,470,505 shares outstanding.

What happened to Actuate Therapeutics, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Actuate Therapeutics, Inc.?

Currently, no hedge funds are holding shares in ACTU

Actuate Therapeutics, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

66.13%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Actuate Therapeutics, Inc.

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Actuate Therapeutics, Inc. (ACTU) Earnings & Revenues

Currently, no data available

Please return soon. This page is being updated.

Historic Earnings Reports

ACTU Stock 12 Month Forecast

Average Price Target

$20.00

▲(147.83% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","9":"$9","13":"$13","17":"$17","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9,13,17,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.13,7.196923076923077,8.263846153846155,9.330769230769231,10.397692307692308,11.464615384615385,12.531538461538464,13.598461538461539,14.665384615384617,15.732307692307693,16.79923076923077,17.866153846153846,18.933076923076925,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.13,7.196923076923077,8.263846153846155,9.330769230769231,10.397692307692308,11.464615384615385,12.531538461538464,13.598461538461539,14.665384615384617,15.732307692307693,16.79923076923077,17.866153846153846,18.933076923076925,{"y":20,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.13,7.196923076923077,8.263846153846155,9.330769230769231,10.397692307692308,11.464615384615385,12.531538461538464,13.598461538461539,14.665384615384617,15.732307692307693,16.79923076923077,17.866153846153846,18.933076923076925,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.15,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.05,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.92,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.83,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.92,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.96,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.03,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.24,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.24,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.7,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.13,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >